A cancer drug linked to rapid growth spurts in children has caught the attention of teenagers looking to gain an extra few inches in height.
Erdafitinib, a medicine designed to treat advanced cancer, has been linked to extraordinary growth spurts in children receiving treatment for brain tumours. Reports of these effects have fuelled interest among people seeking to maximise their height – so-called “heightmaxxing”, though it’s unclear how many are actually taking the drug. However, the trend is visible enough online that TikTok has banned some accounts from promoting it.
However, the same treatment that appears to stimulate height can also interfere with normal skeletal development, potentially causing permanent damage.
Erdafitinib is a targeted cancer drug approved for treating certain patients with advanced bladder cancer. It is also used experimentally for certain types of brain tumour in children. It blocks a family of proteins called fibroblast growth factor receptors, or FGFRs.
These receptors act like molecular switches, controlling how cells grow, divide and survive. In some cancers, genetic changes leave these switches permanently on, causing cells to multiply uncontrollably. Erdafitinib interferes with these signals, slowing cancer cell growth.
